Target intelligence / Profile preview

Colonic mucosa and enterocytes

Molecular classification
Other
01

Overview

The colonic mucosa is the innermost layer of the large intestine, consisting of a simple columnar epithelium, the lamina propria, and the muscularis mucosae (StatPearls, Histology, Colon, 2023). The primary cell type within this layer is the enterocyte, which specializes in the absorption of water, electrolytes, and products of bacterial fermentation such as short-chain fatty acids (PubMed, PMID: 28607316). Beyond absorption, the colonic mucosa serves as a vital semi-permeable barrier that protects the body from luminal pathogens and toxins while facilitating immune tolerance (Nature Reviews Gastroenterology & Hepatology, 2017). Pathological changes in the colonic mucosa and enterocyte function are hallmarks of diseases such as ulcerative colitis and Crohn's disease, where the barrier is compromised and immune infiltration occurs (NIH, NIDDK, 2020). Although "Colonic mucosa and enterocytes" refers to a tissue and cell type rather than a single molecular target, it is the primary site for the delivery and action of many gastrointestinal therapies, including aminosalicylates and site-specific corticosteroids (PubChem, CID: 4075).

Other names
Intestinal mucosaColonic epitheliumIntestinal epithelial cellsLarge intestinal mucosa
02

Mechanism of action

Pharmacological agents do not target the colonic mucosa as a single molecule; instead, they modulate various pathways within the mucosal environment. For example, 5-aminosalicylates provide local anti-inflammatory effects, while biologics like vedolizumab target specific integrins to prevent lymphocyte homing to the colonic mucosa (PubChem, CID: 4075; Nature Reviews Gastroenterology & Hepatology, 2017).

03

Biological functions

Absorption of water and electrolytesIntestinal barrier functionMucus secretionImmune surveillanceShort-chain fatty acid metabolism
04

Disease associations

Inflammatory bowel diseaseUlcerative colitisCrohn's diseaseColorectal cancerInfectious colitis
05

Safety considerations

Mucosal ulcerationIncreased intestinal permeabilityMalabsorption syndromesRisk of opportunistic gastrointestinal infections
06

Interacting drugs

Mesalamine

4 more in the full profile.

07

Biomarkers

Fecal calprotectinFecal lactoferrinC-reactive proteinVillin-1

Beyond the preview

Go deeper on Colonic mucosa and enterocytes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Colonic mucosa and enterocytes.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call